NeoGenomics, Inc. (OTC BB: NGNM) is known as the only publicly-traded pure-play laboratory testing service provider that has a specific focus on high revenue cancer genetics testing. The combination of advances in technology and genetic research, with the complete sequencing of the human genome, sophisticated new scientific testing tools to diagnose and treat diseases have been made possible. The company’s two facilities in Ft. Myers, Fla., and other facilities in Nashville, Tenn. and Irvine, Calif provide state of the art genetic testing. For further information, visit the Company’s web site at www.neogenomics.org.
- 18 years ago
QualityStocks
NeoGenomics, Inc. (OTC BB: NGNM)
Tags Rodman & Renshaw
Related Post
-
The Software Premium: How SPARC AI Is Betting That Code, Not Airframes, Decides the Next Drone War
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid…
-
Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Leverages US Jurisdiction Advantage as Sovereign Gold Demand Reshapes Market
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid…
-
Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy
Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results,…